These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 34195671)

  • 1. Optimized immunofluorescence staining protocol for imaging germinal centers in secondary lymphoid tissues of vaccinated mice.
    Fra-Bido S; Walker SA; Innocentin S; Linterman MA
    STAR Protoc; 2021 Sep; 2(3):100499. PubMed ID: 34195671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
    Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
    Front Immunol; 2021; 12():779212. PubMed ID: 34899739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
    Normark J; Vikström L; Gwon YD; Persson IL; Edin A; Björsell T; Dernstedt A; Christ W; Tevell S; Evander M; Klingström J; Ahlm C; Forsell M
    N Engl J Med; 2021 Sep; 385(11):1049-1051. PubMed ID: 34260850
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of Platelets Activation Prior to Second Doses of Covid-19 Vaccine After Vaccine-Induced Immune Thrombotic Thrombocytopenia.
    Roberge G; Carrier M
    Clin Appl Thromb Hemost; 2022; 28():10760296221086283. PubMed ID: 35275495
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia.
    Crickx E; Moulis G; Ebbo M; Terriou L; Briantais A; Languille L; Limal N; Guillet S; Michel M; Mahevas M; Godeau B
    Br J Haematol; 2021 Dec; 195(5):703-705. PubMed ID: 34467525
    [No Abstract]   [Full Text] [Related]  

  • 12. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    Andrews N; Tessier E; Stowe J; Gower C; Kirsebom F; Simmons R; Gallagher E; Thelwall S; Groves N; Dabrera G; Myers R; Campbell CNJ; Amirthalingam G; Edmunds M; Zambon M; Brown K; Hopkins S; Chand M; Ladhani SN; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Jan; 386(4):340-350. PubMed ID: 35021002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying Follicular Regulatory T Cells by Confocal Microscopy.
    Vanderleyden I; Linterman MA
    Methods Mol Biol; 2017; 1623():87-93. PubMed ID: 28589349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Vaccine Combination Was Superior in Real-world Study.
    Abbasi J
    JAMA; 2021 Dec; 326(22):2250. PubMed ID: 34905046
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of the Germinal Center Reaction in Tissue Sections.
    Dominguez-Sola D; Cattoretti G
    Methods Mol Biol; 2017; 1623():1-20. PubMed ID: 28589343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.
    Fischer RJ; van Doremalen N; Adney DR; Yinda CK; Port JR; Holbrook MG; Schulz JE; Williamson BN; Thomas T; Barbian K; Anzick SL; Ricklefs S; Smith BJ; Long D; Martens C; Saturday G; de Wit E; Gilbert SC; Lambe T; Munster VJ
    Nat Commun; 2021 Oct; 12(1):5868. PubMed ID: 34620866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.
    Schmidt T; Klemis V; Schub D; Mihm J; Hielscher F; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Schneitler S; Becker SL; Gärtner BC; Sester U; Sester M
    Nat Med; 2021 Sep; 27(9):1530-1535. PubMed ID: 34312554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of both B-cell intrinsic alterations as well as non-hematopoietic-derived factors in the enhanced immune response of the NOD mouse.
    Banday VS; Thyagarajan R; Lejon K
    Autoimmunity; 2017 Sep; 50(6):363-369. PubMed ID: 28686488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 timeline of events.
    Webster P
    Nat Med; 2021 Dec; 27(12):2054-2055. PubMed ID: 34907389
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased B Cell Selection Stringency In Germinal Centers Can Explain Improved COVID-19 Vaccine Efficacies With Low Dose Prime or Delayed Boost.
    Garg AK; Mittal S; Padmanabhan P; Desikan R; Dixit NM
    Front Immunol; 2021; 12():776933. PubMed ID: 34917089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.